Catálogo de publicaciones - libros

Compartir en
redes sociales


Risk-sharing in the Pharmaceutical Industry: The Case of Out-licensing

Gerrit Reepmeyer

Resumen/Descripción – provisto por la editorial

No disponible.

Palabras clave – provistas por la editorial

No disponibles.

Disponibilidad
Institución detectada Año de publicación Navegá Descargá Solicitá
No detectada 2006 SpringerLink

Información

Tipo de recurso:

libros

ISBN impreso

978-3-7908-1667-9

ISBN electrónico

978-3-7908-1668-6

Editor responsable

Springer Nature

País de edición

Reino Unido

Fecha de publicación

Información sobre derechos de publicación

© Physica-Verlag Heidelberg 2006

Cobertura temática

Tabla de contenidos

Introduction

Palabras clave: Risk Management; Pharmaceutical Company; External Partner; Pharmaceutical Firm; Biotechnology Firm.

Pp. 1-27

Key Issues in Managing Pharmaceutical Innovation

Palabras clave: Pharmaceutical Industry; Pharmaceutical Company; Generic Drug; Patent Protection; Mass Customization.

Pp. 29-64

Risk-sharing as New Paradigm in Pharma R&D Collaborations

Palabras clave: Intellectual Property; Pharmaceutical Company; External Partner; Pharmaceutical Firm; Marketing Capability.

Pp. 65-88

Case Studies on Risk-sharing in Pharma R&D Collaborations

Palabras clave: Pulmonary Arterial Hypertension; Pharmaceutical Company; Venture Capital; License Agreement; External Partner.

Pp. 89-129

Characteristics of Risk-sharing in Pharma R&D Collaborations

Palabras clave: Pharmaceutical Company; Venture Capital; Venture Capital Investor; External Partner; Pharmaceutical Firm.

Pp. 131-181

Theoretical Basis for Risk-sharing in Pharma R&D Collaborations

Palabras clave: Pharmaceutical Company; Adverse Selection; Expected Profit; Indifference Curve; Potential Buyer.

Pp. 183-202

Managerial Recommendations for Risk-sharing in Pharma R&D Collaborations

Palabras clave: Pharmaceutical Company; Managerial Recommendation; Price Setting; Risk Transferability; Product Coverage.

Pp. 203-244

Conclusion

Palabras clave: Pharmaceutical Company; Adverse Selection; Price Setting; Case Study Analysis; Risk Transferability.

Pp. 245-262